<DOC>
	<DOCNO>NCT00002358</DOCNO>
	<brief_summary>To provide oral sorivudine ( BV-araU ) pediatric HIV-infected patient varicella-zoster viral disease fail intolerant alternative therapy .</brief_summary>
	<brief_title>A Study BV-araU Treatment Varicella-Zoster Viral Disease ( VZV ) HIV-Infected Children Who Have Not Had Success With Who Can Take Other Treatments VZV</brief_title>
	<detailed_description>Any physician qualified treat pediatric AIDS patient may enroll patient study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sorivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection . Cutaneous , visceral , ocular varicellazoster viral infection . Refractory intolerant acyclovir foscarnet therapy . Consent parent guardian . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Inability take oral capsule tolerate liquid . Concurrent Medication : Excluded : 5flucytosine , 5fluorouracil , highdose prednisone , probenecid . Patients follow prior condition exclude : History immediate hypersensitivity nucleoside analogues . Prior Medication : Excluded : 5flucytosine , 5fluorouracil , highdose prednisone , probenecid within 4 week prior study entry . Required : Prior acyclovir foscarnet .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Herpes Zoster</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>sorivudine</keyword>
	<keyword>Chickenpox</keyword>
</DOC>